CaiLian Press reported on November 6 (edited by Malan) that the bidding war around obesity biotech company Metsera is becoming increasingly fierce. It is reported that Pfizer plans to raise its offer and compete with Novo Nordisk again.

In September, Pfizer made a tender offer to acquire Metsera with a total price of $7.3 billion, and the two companies were close to reaching an agreement. However, the deal was disrupted by the sudden intervention of Novo Nordisk last Thursday.

Novo Nordisk offered $10 billion to acquire Metsera. This price, significantly higher than Pfizer's, led Metsera to reject Pfizer's offer, sparking a competition between the two companies. Pfizer filed lawsuits against Novo Nordisk and Metsera last F

However, on Wednesday, a judge in Delaware, USA, dismissed Pfizer's lawsuit request, becoming the latest twist in this bidding war and forcing Pfizer to seek new response strategies.

Meanwhile, Daniel Guarnera, the director of the Competition Bureau at the Federal Trade Commission in the United States, also emphasized in an open letter on Wednesday that the merger structure of Novo Nordisk and Metsera could potentially raise anti

Metsera, established in 2022, is developing a series of oral and injectable therapeutic products that target different sites. The products demonstrate the potential for monthly dosing in clinical trials, which is less frequent than weekly dosing, suc

Some industry insiders analyze that the core value of Metsera lies in its aim to solve the current pain points of GLP-1 drugs in terms of efficacy, tolerability, and dosing frequency. However, its two core products, MET-097i and MET-233i, are still i

For Pfizer, which has been unable to introduce weight loss drugs for competition, Metsera is a golden key to enter the weight loss drug market; while for Novo Nordisk, Metsera is the key to improve its competitiveness and further strengthen its produ

Both companies are unwilling to easily give up on Metsera, which has led to a rapidly changing bidding war and could potentially determine the future landscape of the $150 billion weight loss drug market.

However, TD Cowen analyst Michael Nedelcovych pointed out in a report that it is not yet clear whether there is a significant difference between Metsera's weight loss drug and Novo Nordisk's own drug. The value of Metsera mainly lies in the prospect

On the other hand, Jared Holz, a stock strategist at Ruixiu Healthcare, stated that the acquisition of Metsera by Novo Nordisk is motivated by both self-interest and the desire to prevent Metsera from falling into the hands of Pfizer or other pharmac

Facing the strength of Nuhe and Nord, Pfizer has also expressed its determination not to yield. Pfizer's Chief Financial Officer Dave Denton emphasized on Tuesday that the company will exercise all its rights in accordance with the law, and there are